MapLight Therapeutics, Inc.
MPLT
Positions held
Your positionsMPLT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $508.52M | Enterprise value | $121.62M | Trailing P/E | — | Forward P/E | -2.68 |
| PEG | — | Price / book | 1.19 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -111.5% | ROA | -67.1% | Debt / equity | 0.01 |
| Current ratio | 16.52 | Free cash flow | -$95.21M | Analyst recommendation | strong_buy | Mean target | $26.54 |
| 52w high | $40.43 | 52w low | $8.92 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$60.2M | -$60.7M | -$79.5M | -$29.4M | -$29.8M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$63.5M | -$64.5M | -$83.4M | -$31.5M | -$30.7M |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | — | — |
| Op margin | — | — | — |
| Net income | -$161M | — | — |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$169M | — | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Guggenheim Initiates MapLight Therapeutics at Neutral
2026-09-09 · IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
2026-09-09 · MapLight Therapeutics to Participate in Upcoming Investor Conference
2026-08-18 · AstraZeneca scores in lung cancer; Sandoz inks a China deal
2026-08-13 · MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-08-13 · Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-08-13 · MapLight Therapeutics Launching $150 Million Private Placement Financing
2026-08-13 · MapLight Therapeutics Announces $150 Million Private Placement Financing
2026-08-10 · UBS Downgrades MapLight Therapeutics to Neutral From Buy, Adjusts PT to $13 From $52
2026-07-29 · MapLight CEO on what investors missed in the biotech’s schizophrenia data
Price (daily)
Full chart · RSI · MACD · patterns